Stock 1SXP SCHOTT PHARMA AG & CO. KGAA
Add to a list
To use this feature you must be a member
Log inSign up

Ratings SCHOTT Pharma AG & Co. KGaA

Equities

1SXP

DE000A3ENQ51

Real-time Estimate Tradegate
Other stock markets
 07:28:20 2024-07-03 am EDT 		5-day change 1st Jan Change
30.45 EUR -2.84% Intraday chart for SCHOTT Pharma AG & Co. KGaA +15.50% -9.05%
11:53am SCHOTT PHARMA : Jefferies remains Neutral ZD
Jul. 02 Deutsche Bank raises target for Schott Pharma to 37 euros - 'Buy' DP

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.

Weaknesses

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.09 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
SCHOTT PHARMA AG & CO. KGAA Stock SCHOTT Pharma AG & Co. KGaA
-9.82% 5.07B -
ABBOTT LABORATORIES Stock Abbott Laboratories
-6.24% 180B
C+
MEDTRONIC PLC Stock Medtronic plc
-6.08% 99.21B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.98% 66.25B
A
DEXCOM, INC. Stock DexCom, Inc.
-9.35% 44.74B
B-
CENCORA, INC. Stock Cencora, Inc.
+8.34% 43.82B
B-
HOYA CORPORATION Stock Hoya Corporation
+10.35% 41.96B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+11.88% 28.98B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
-8.38% 23.5B
A-
TERUMO CORPORATION Stock Terumo Corporation
+16.18% 24.07B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 1SXP Stock
  4. Ratings SCHOTT Pharma AG & Co. KGaA